Should Warfarin Be Held Before Elective EGD?
For a diagnostic EGD with or without biopsies, warfarin should NOT be held—continue warfarin with INR monitoring to ensure it remains within therapeutic range. For high-risk therapeutic procedures (polypectomy, EMR, ESD), warfarin should be stopped 5 days before the procedure with INR verification <1.5 prior to the procedure 1.
Risk Stratification Framework
The decision hinges on whether your EGD is low-risk or high-risk:
Low-Risk Procedures (Continue Warfarin)
- Diagnostic EGD with mucosal biopsies
- Biliary/pancreatic stenting
- Esophageal/enteral stenting
- EUS without sampling
High-Risk Procedures (Hold Warfarin)
- Polypectomy
- Endoscopic mucosal resection (EMR)
- Endoscopic submucosal dissection (ESD)
- Stricture dilation
- Variceal therapy
- PEG placement
- EUS with sampling or intervention 1
Management Protocol for Low-Risk EGD
Continue warfarin without interruption 1:
- Check INR during the week before endoscopy
- If INR is within therapeutic range: proceed with usual daily dose
- If INR is above therapeutic range but <5: reduce daily warfarin dose until INR returns to therapeutic range
- If INR >5: defer the endoscopy and contact anticoagulation clinic for management
- Never perform the procedure if INR exceeds 3.5 2
This approach is supported by strong guideline recommendations recognizing that diagnostic procedures with biopsies carry <1% bleeding risk even on continued anticoagulation 2.
Management Protocol for High-Risk EGD
The approach depends on thromboembolic risk stratification:
Low Thromboembolic Risk Patients
(e.g., atrial fibrillation with CHA₂DS₂-VASc <4, no recent stroke/TIA)
- Stop warfarin 5 days before the procedure 1
- Check INR prior to procedure to ensure <1.5 (ideally <2.0) 1, 2
- Resume warfarin the evening of the procedure with usual daily dose 1
- Check INR 1 week later to ensure adequate anticoagulation 1
- No bridging anticoagulation needed 1
High Thromboembolic Risk Patients
(e.g., mechanical heart valve, AF with recent stroke/TIA within 3 months, AF with mitral stenosis, previous VTE on anticoagulation with target INR 3.5)
- Stop warfarin 5 days before the procedure 1
- Two days after stopping warfarin, commence therapeutic dose LMWH 1
- Administer last dose of LMWH at least 24 hours prior to procedure 1
- Check INR prior to procedure to ensure <1.5 1
- Resume warfarin evening of procedure with usual dose 1
- Restart therapeutic LMWH the day after procedure 1
- Continue LMWH until satisfactory INR achieved 1
Critical Pitfalls to Avoid
Do not routinely bridge with heparin for low thromboembolic risk patients—this significantly increases bleeding risk without reducing thrombotic events. The 2021 BSG/ESGE guidelines explicitly recommend against routine bridging except for mechanical heart valves and very high-risk conditions 1.
Do not use fresh frozen plasma for warfarin reversal in acute GI bleeding—if reversal is needed, prothrombin complex concentrate is preferred 3, 4.
Do not hold warfarin longer than necessary—the anticoagulant effect persists beyond 24 hours, and INR typically returns to <1.5 within 5 days in most patients 5, 6. Patients on lower maintenance doses (<25 mg/week) may require slightly longer interruption 6.
Evidence Quality and Nuances
The 2021 BSG/ESGE guidelines 1 represent the highest quality and most recent evidence, with strong recommendations based on moderate-to-high quality evidence for high-risk procedures. The recommendation to continue warfarin for low-risk procedures is based on moderate-quality evidence recognizing the minimal bleeding risk (<1%) of diagnostic endoscopy with biopsies 1, 2.
The Asian guidelines 2 are slightly more conservative, recommending deferral if INR exceeds 3.5 before any endoscopy, which provides an additional safety margin.
The key principle: balance bleeding risk against thrombotic risk, with the understanding that thrombotic complications (stroke, valve thrombosis) carry higher morbidity and mortality than most endoscopic bleeding events.